Intercept is on track to be acquired by Alfasigma at a significant premium compared to recent prices.
Proposed all-cash acquisition will materially expand Alfasigma’s portfolio in gastroenterology and hepatology and its presence in the U.S. marketTransaction price represents an 82% premium to Intercept’s closing price on September 25, 2023Alfasigma adds Ocaliva®, the only FDA approved second-line treatment for PBC, a progressive autoimmune disease affecting the liver, which generated revenue of $152 million in 1H 2023Strengthens Alfasigma’s pipeline, including the addition of a novel fixed-dose
The continued momentum is a result of CymaBay's announcement yesterday of positive top-line results from a late-stage clinical study evaluating experimental drug seladelpar in treating primary biliary cholangitis (PBC), a rare chronic inflammatory liver disease. The great news for CymaBay, though, is that seladelpar appears to have a key advantage over those other PBC treatments. The results from the company's phase 3 study found that it significantly reduced itching, which is a major issue for many PBC patients.